Preparation and evaluation of tacrolimus-loaded nanoparticles for lymphatic delivery

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 74, Issue 2, 2010, Pages 164-171

  Shin, Sae Byeok ^a   Cho, Hea Young ^b   Kim, Dae Duk ^c   Choi, Han Gon ^d   Lee, Yong Bok ^a  

^a Chonnam National University   (South Korea)

^b Korea Food and Drug Administration   (South Korea)

^c Seoul National University   (South Korea)

^d Yeungnam University   (South Korea)

Author keywords

Emulsification diffusion method; Lymphatic delivery; Nanoparticles; Pharmacokinetics; Tacrolimus

Indexed keywords

CYCLOSPORIN A; MACROGOL; NANOPARTICLE; POLOXAMER; POLYGLACTIN; TACROLIMUS;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AXILLARY LYMPH NODE; CONTROLLED STUDY; DIFFUSION; DISSOLUTION; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; IN VITRO STUDY; MALE; MEAN RESIDENCE TIME; MESENTERY LYMPH NODE; NANOEMULSION; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PLASMA CONCENTRATION-TIME CURVE; RAT; SCANNING ELECTRON MICROSCOPY; SINGLE DRUG DOSE; TARGET ORGAN; THERMAL ANALYSIS; TRANSMISSION ELECTRON MICROSCOPY; X RAY DIFFRACTION;

ANIMALS; DRUG CARRIERS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; INJECTIONS, INTRAVENOUS; LYMPH NODES; MALE; NANOPARTICLES; PHYSICOCHEMICAL PROCESSES; POLYETHYLENE GLYCOLS; POLYGLACTIN 910; RATS; RATS, SPRAGUE-DAWLEY; TACROLIMUS; TISSUE DISTRIBUTION;

EID: 75449119910     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2009.08.006     Document Type: Article

References (44)

1. Wong S.H.Y. Therapeutic drug monitoring for immunosuppressants. Clin. Chim. Acta 313 (2001) 241-253
2. Brazelton T.R., and Randall M.E. Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide. Curr. Opin. Immunol. 8 (1996) 710-720
3. Fung J.J. Tacrolimus and transplantation: a decade in review. Transplantation 77 (2004) S41
4. Jurewicz W.A. Tacrolimus versus cyclosporin immunosuppression: long-term outcome in renal transplantation. Nephrol. Dial. Transplant. 18 (2003) i7-11
5. Wiesner R.H. Long-term comparison of tacrolimus versus cyclosporine in liver transplantation. Elsevier 30 (1998) 1399-1400
6. Haufroid V., Mourad M., Van Kerckhove V., Wawrzyniak J., De Meyer M., Eddour D.C., Malaise J., Lison D., Squifflet J.P., and Wallemacq P. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 14 (2004) 147-154
7. Choi J.H., Lee Y.J., Jang S.B., Lee J.E., Kim K.H., and Park K. Influence of the CYP3A5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects. Br. J. Clin. Pharmacol. 64 (2007) 185-191
8. Yamauchi A., Ieiri I., Kataoka Y., Tanabe M., Nishizaki T., Oishi R., Higuchi S., Otsubo K., and Sugimachi K. Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. Transplantation 74 (2002) 571
9. Thervet E., Anglicheau D., King B., Schlageter M.H., Cassinat B., Beaune P., Legendre C., and Daly A.K. Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients12. Transplantation 76 (2003) 1233
10. Password F. Tacrolimus whole blood concentrations correlate closely to side-effects in renal transplant recipients. Br. J. Clin. Pharmacol. 48 (1999) 445-448
11. Kingsley J.D., Dou H., Morehead J., Rabinow B., Gendelman H.E., and Destache C.J. Nanotechnology: a focus on nanoparticles as a drug delivery system. J. Neuroimmune Pharmacol. 1 (2006) 340-350
12. Song C.X., Labhasetwar V., Murphy H., Qu X., Humphrey W.R., Shebuski R.J., and Levy R.J. Formulation and characterization of biodegradable nanoparticles for intravascular local drug delivery. J. Control. Release 43 (1997) 197-212
13. Soppimath K.S., Aminabhavi T.M., Kulkarni A.R., and Rudzinski W.E. Biodegradable polymeric nanoparticles as drug delivery devices. J. Control. Release 70 (2001) 1-20
14. Brigger I., Dubernet C., and Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev. 54 (2002) 631-651
15. Muller R.H., and Keck C.M. Challenges and solutions for the delivery of biotech drugs: a review of drug nanocrystal technology and lipid nanoparticles. J. Biotechnol. 113 (2004) 151-170
16. Sinha R., Kim G.J., Nie S., and Shin D.M. Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol. Cancer Ther. 5 (2006) 1909
17. Li Y.P., Pei Y.Y., Zhang X.Y., Gu Z.H., Zhou Z.H., Yuan W.F., Zhou J.J., Zhu J.H., and Gao X.J. PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats. J. Control. Release 71 (2001) 203-211
18. Choi S.W., Kim W.S., and Kim J.H. Surface-functionalized nanoparticles for controlled drug delivery. NanoBiotech. Protocols 10 (2005) 121-131
19. Lu W., Zhang Y., Tan Y.Z., Hu K.L., Jiang X.G., and Fu S.K. Cationic albumin-conjugated pegylated nanoparticles as novel drug carrier for brain delivery. J. Control. Release 107 (2005) 428-448
20. Tobio M., Sanchez A., Vila A., Soriano II I., Evora C., Vila-Jato J.L., and Alonso M.J. The role of PEG on the stability in digestive fluids and in vivo fate of PEG-PLA nanoparticles following oral administration. Colloids Surf. B: Biointerf. 18 (2000) 315-323
21. Gref R., Luck M., Quellec P., Marchand M., Dellacherie E., Harnisch S., Blunk T., and Muller R.H. Stealth, corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf. B: Biointerf. 18 (2000) 301-313
22. Nishioka Y., and Yoshino H. Lymphatic targeting with nanoparticulate system. Adv. Drug Deliv. Rev. 47 (2001) 55-64
23. Borhade V., Nair H., and Hegde D. Design and evaluation of self-microemulsifying drug delivery system (SMEDDS) of tacrolimus. AAPS PharmSciTech 9 (2008) 13-21
24. Ikomi F., Hanna G.K., and Schmid-Schonbein G.W. Mechanism of colloidal particle uptake into the lymphatic system: basic study with percutaneous lymphography. Radiology 196 (1995) 107-113
25. Uno T., Kazui T., Suzuki Y., Hashimoto H., Suzuki K., and Muhammad B.A.H. Pharmacokinetic advantages of a newly developed tacrolimus oil-in-water-type emulsion via the enteral route. Lipids 34 (1999) 249-254
26. Hawley A.E., Davis S.S., and Illum L. Targeting of colloids to lymph nodes: influence of lymphatic physiology and colloidal characteristics. Adv. Drug Deliv. Rev. 17 (1995) 129-148
27. Kwon H.Y., Lee J.Y., Choi S.W., Jang Y., and Kim J.H. Preparation of PLGA nanoparticles containing estrogen by emulsification-diffusion method. Colloids Surf. A: Physicochem. Eng. Asp. 182 (2001) 123-130
28. Moinard-Checot D., Chevalier Y., Briancon S., Beney L., and Fessi H. Mechanism of nanocapsules formation by the emulsion-diffusion process. J. Colloid Interf. Sci. 317 (2008) 458-468
29. Quintanar-Guerrero D., Fessi H., Allemann E., and Doelker E. Influence of stabilizing agents and preparative variables on the formation of poly (d,l-lactic acid) nanoparticles by an emulsification-diffusion technique. J. Pharm. 143 (1996) 133-141
30. Song K.C., Lee H.S., Choung I.Y., Cho K.I., Ahn Y., and Choi E.J. The effect of type of organic phase solvents on the particle size of poly (d,l-lactide-co-glycolide) nanoparticles. Colloids Surf. A: Physicochem. Eng. Asp. 276 (2006) 162-167
31. Layre A.M., Couvreur P., Richard J., Requier D., Eddine Ghermani N., and Gref R. Freeze-drying of composite core-shell nanoparticles. Drug Dev. Ind. Pharm. 32 (2006) 839-846
32. Uno T., Yamaguchi T., Li X.K., Suzuki Y., Hashimoto H., Harada Y., Kimura T., and Kazui T. The pharmacokinetics of water-in-oil-in-water-type multiple emulsion of a new tacrolimus formulation. Lipids 32 (1997) 543-548
33. Christians U., Jacobsen W., Serkova N., Benet L.Z., Vidal C., Sewing K.F., Manns M.P., and Kirchner G.I. Automated, fast and sensitive quantification of drugs in blood by liquid chromatography-mass spectrometry with on-line extraction: immunosuppressants. J. Chromatogr. B: Biomed. Sci. Appl. 748 (2000) 41-53
34. Park S.I., Felipe C.R., Pinheiro-Machado P.G., Garcia R., Tedesco-Silva H., and Medina-Pestana J.O. Circadian and time-dependent variability in tacrolimus pharmacokinetics. Fundam. Clin. Pharmacol. 21 (2007) 191-197
35. Streit F., Armstrong V.W., and Oellerich M. Rapid liquid chromatography-tandem mass spectrometry routine method for simultaneous determination of sirolimus, everolimus, tacrolimus, and cyclosporin a in whole blood. Clin. Chem. 48 (2002) 955-958
36. Gabrielsson J., and Weiner D. Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications. second ed. (2000), Swedish Pharmaceutical Press, Stockholm, Sweden
37. Gibaldi M., and Perrier D. Pharmacokinetics. second ed. (1982), Dekker, NY, USA
38. Freitas C., and Müller R.H. Effect of light and temperature on zeta potential and physical stability in solid lipid nanoparticle (SLN™) dispersions. Int. J. Pharm. 168 (1998) 221-229
39. Wallemacq P.E., and Reding R. FK506 (tacrolimus), a novel immunosuppressant in organ transplantation: clinical, biomedical, and analytical aspects. Clin. Chem. 39 (1993) 2219-2228
40. Strawhecker K.E., and Manias E. Structure and properties of poly (vinyl alcohol)/Na montmorillonite nanocomposites. Chem. Mater. 12 (2000) 2943-2949
41. Mu L., and Feng S.S. PLGA/TPGS nanoparticles for controlled release of paclitaxel: effects of the emulsifier and drug loading ratio. Pharm. Res. 20 (2003) 1864-1872
42. Yoo H.S., Lee K.H., Oh J.E., and Park T.G. In vitro and in vivo anti-tumor activities of nanoparticles based on doxorubicin-PLGA conjugates. J. Control. Release 68 (2000) 419-431
43. Venkateswarlu V., and Manjunath K. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J. Control. Release 95 (2004) 627-638
44. Fawaz F., Bonini F., Maugein J., and Lagueny A.M. Ciprofloxacin-loaded polyisobutylcyanoacrylate nanoparticles: pharmacokinetics and in vitro antimicrobial activity. Int. J. Pharm. 168 (1998) 255-259